Clinical trials: Levosimendan
Heart Failure
Levosimendan in High Risk Heart Valve Surgery
Prospective, randomized, double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Study hypothesis: Levosimendan diminishes the need for adrenergic inotropic drugs and morbidity and…
- Trial name
- NCT00154115
- Testing
- levosimendan
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- Kuopio University Hospital
Low Cardiac Output Syndrome
Levosimendan Administration in Neonates With Transposition of the Great Arteries
Calcium sensitizer drugs such as Levosimendan may exert anti-ischemic effect in addition to positive inotropic and anti-stunning effects mediated by the opening of ATP-sensitive potassium (KATP) channels.
- Trial name
- NCT01120106
- Testing
- levosimendan
- Where
- Italy
- Volunteers
- 63 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Acute Heart Failure
Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units
To describe pharmacokinetics of levosimendan in neonates and children supported or not with extracorporeal circulation devices (ECMO, CRRT)
- Trial name
- PALMAréa (NCT03681379)
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Nantes University Hospital
Acute Kidney Injury
Levosimendan in Acute Kidney Injury Study
We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients.
- Trial name
- LAKIS (NCT01720030)
- Testing
- Levosimendan, Conventional therapy
- Where
- Netherlands
- Volunteers
- 68 people
- Sponsor
- VieCuri Medical Centre
Cardiac Surgery
Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery
This study aims to examine the efficacy of levosimendan in terms of reducing postoperative mortality and severe morbidity in patients undergoing non-emergent surgery for coronary revascularisation with or without ischaemic mitral…
- Trial name
- NCT01595737
- Testing
- Levosimendan
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Systolic Heart Failure
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
Rehospitalizations due to exacerbation of chronic heart failure are an important problem for patients suffering from heart failure.
- Trial name
- NCT03764722
- Testing
- Levosimendan
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid
Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction
A Prospective, multicenter, randomized (two arms, parallel groups); double-blind, placebo-controlled in order to assess the ability of preoperative levosimendan to prevent post-operative low cardiac output in high-risk patients…
- Trial name
- LEONARD (NCT05233202)
- Testing
- Levosimendan
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Decompensation
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
- Trial name
- NCT02973620
- Testing
- Levosimendan
- Sponsor
- Tenax Therapeutics, Inc.
Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction
Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
- Conditions
- Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Trial name
- NCT03624010
- Testing
- Levosimendan
- Where
- 9 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tenax Therapeutics, Inc.
ST Elevation Myocardial Infarction, Heart Failure
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can significantly reduce mortality, but patients may still have heart failure and adverse cardiovascular events due to massive myocardial loss.
- Trial name
- NCT04970238
- Testing
- Levosimendan
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhijun Sun
Acute Kidney Injury, Renal Insufficiency, Acute
Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery
Acute kidney injury (AKI) is a common complication after cardiac surgery. Mismatch in renal oxygen demand-supply may be an important pathogenetic factor.
- Trial name
- LEVOAKI (NCT02531724)
- Testing
- Levosimendan
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Sahlgrenska University Hospital
Acute Decompensated Heart Failure (ADHF)
Levosimendan in Acute Decompensated Heart Failure
Acute decompensated heart failure (ADHF) is one of the major causes of hospitalization and mortality worldwide. Despite advances in medical treatments, managing ADHF remains complex, especially in high-risk populations.
- Trial name
- NCT07262723
- Testing
- Levosimendan, Standard care
- Where
- 6 sites in Bangladesh
- Volunteers
- 332 people
- Sponsor
- Chittagong Medical College
Left Ventricular Dysfunction
Pharmacokinetics of Inhaled Levosimendan
Determination of biological availability, time-to-peak and elimination half-life of inhaled levosimendan by administration of an inhaled- and intravenous dose of levosimendan.
- Trial name
- Symbiov (NCT06387862)
- Testing
- Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled, Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Universitair Ziekenhuis Brussel
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Efficacy and Clinical Outcomes of Levosimendan in E-CPR
Treatment of refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR) may be augmented with Extracorporeal membrane oxygenation (ECMO) to re-establish perfusion in the absence of return of spontaneous circulation.
- Trial name
- ECPR (NCT05730907)
- Testing
- Levosimendan
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Acute Decompensated Heart Failure (ADHF), Cardiorenal Syndrome (CRS)
Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
This study aimed to assess and compare the cardiac, renal, and clinical efficacy of Levosimendan (LEV), Dobutamine (DOB), and milrinone (MIL) in cases with acute decompensated heart failure (ADHF) complicated by renal impairment…
- Trial name
- NCT07186062
- Testing
- Levosimendan, Dobutamine, Milrinone
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Coronary Heart Disease
Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
- Trial name
- NCT00130871
- Testing
- levosimendan
- Where
- 2 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Orion Corporation, Orion Pharma
Transesophageal Echocardiography, Acute Respiratory Distress Syndrome
Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV
Acute respiratory distress syndrome (ARDS) is often complicated by right ventricular dysfunction (RVD), Acute cor pulmonale is the most serious form of ARDS complicated with RVD.Levosimendan is indicated for short-term treatment…
- Conditions
- Transesophageal Echocardiography, Acute Respiratory Distress Syndrome, Right Ventricular Dysfunction
- Trial name
- NCT05768230
- Testing
- levosimendan, 5% glucose injection
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cardiogenic Shock, Arrythmia
Safety Profile of the Combination of Levosimendan and IV Beta Blocker in Cardiogenic Shock: a Retrospective Study
The purpose of this study is to assess the safety profile of the combination of Levosimendan and beta blocker in cardiogenic shock with arrythmia.
- Trial name
- SeLeBêta (NCT04938375)
- Volunteers
- 25 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
The purpose of this study is to compare the effects of levosimendan with dobutamine on heart function in patients suffering of severe chronic heart failure.
- Trial name
- NCT00219388
- Testing
- Levosimendan
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Orion Corporation, Orion Pharma